UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Annals of oncology, 2012-10, Vol.23 (10), p.2605-2612

2012

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of oncology, 2021-01, Vol.32 (1), p.49-57

2021

Volltextzugriff (PDF)

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

European journal of cancer (1990), 2018-10, Vol.102, p.1-9

2018

Volltextzugriff (PDF)

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

European journal of cancer (1990), 2016-09, Vol.64, p.12-21

2016

Volltextzugriff (PDF)

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

ESMO open, 2022-12, Vol.7 (6), p.100601, Article 100601

2022

Volltextzugriff (PDF)

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group

Gynecologic oncology, 2011-10, Vol.123 (1), p.27-32

2011

Volltextzugriff (PDF)

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)

Gynecologic oncology, 2007-12, Vol.107 (3), p.518-525

2007

Volltextzugriff (PDF)

Klinische Ethikkomitees an deutschen Universitätskliniken: Eine Befragung aller Ärztlichen Direktoren und Pflegedirektoren

Deutsche medizinische Wochenschrift, 2004-05, Vol.129 (22), p.1237-1242

2004

Volltextzugriff (PDF)

Neurostimulation for Parkinson's Disease with Early Motor Complications

The New England journal of medicine, 2013-02, Vol.368 (7), p.610-622

2013

Volltextzugriff (PDF)

Risks and complications in 160 living kidney donors who underwent nephroureterectomy

Nephrology, dialysis, transplantation, 2003-12, Vol.18 (12), p.2648-2654

2003

Volltextzugriff (PDF)

Teaching and evaluating breaking bad news: A pre–post evaluation study of a teaching intervention for medical students and a comparative analysis of different measurement instruments and raters

Patient education and counseling, 2012-02, Vol.86 (2), p.210-219

2012

Volltextzugriff (PDF)

LBA19 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)

Annals of oncology, 2021-09, Vol.32, p.S1292-S1293

2021

Volltextzugriff (PDF)

132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial

Annals of oncology, 2021-09, Vol.32, p.S416-S417

2021

Volltextzugriff (PDF)

122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib

Annals of oncology, 2021-09, Vol.32, p.S410-S411

2021

Volltextzugriff (PDF)

Wegener Granulomatose und mikroskopische Polyangiitis: Diagnostische und klinische Ergebnisse bei 54 Patienten im Langzeitverlauf

Deutsche medizinische Wochenschrift, 2000-12, Vol.125 (50), p.1519-1525

2000

Volltextzugriff (PDF)

Validierung des Breast-GPA Scores bei Patientinnen mit Hirnmetastasen eines Mammakarzinoms im BMBC-Register (GBG-79)

Geburtshilfe und Frauenheilkunde, 2018, Vol.78 (10)

2018

Volltextzugriff (PDF)

Abstract P4-08-26: Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-26

2019

Volltextzugriff (PDF)

Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD2-07-PD2-07

2019

Volltextzugriff (PDF)

Abstract PD5-05: Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD5-05-PD5-05

2019

Volltextzugriff (PDF)

Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-20-09

2018

Volltextzugriff (PDF)

Abstract P6-15-01: Withdrawn

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-15-01

2018

Volltextzugriff (PDF)

Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-05-04-OT3-05-04

2018

Volltextzugriff (PDF)

Interstitial nephritis and high titers of PR3-ANCA: an unusual manifestation of ANCA-associated disease

Clinical nephrology, 2005-11, Vol.64 (5), p.383-386

2005

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(73)
Tagungsberichte
(9)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(33)
Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Female
(17)
Adult
(16)
Middle Aged
(14)
Aged
(12)
Biological And Medical Sciences
(12)
Male
(12)
Medical Sciences
(12)
Critical Care Medicine
(9)
Oncology
(8)
General & Internal Medicine
(7)
Germany
(7)
Medicine
(6)
Emergency Medicine
(5)
Medicine & Public Health
(5)
Treatment Outcome
(5)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(4)
Anesthesiology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)

Klinische Ethikkomitees an deutschen Universitätskliniken: Eine Befragung aller Ärztlichen Direktoren und Pflegedirektoren

Neurostimulation for Parkinson's Disease with Early Motor Complications

Risks and complications in 160 living kidney donors who underwent nephroureterectomy

Teaching and evaluating breaking bad news: A pre–post evaluation study of a teaching intervention for medical students and a comparative analysis of different measurement instruments and raters

LBA19 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)

132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial

122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib

Wegener Granulomatose und mikroskopische Polyangiitis: Diagnostische und klinische Ergebnisse bei 54 Patienten im Langzeitverlauf

Validierung des Breast-GPA Scores bei Patientinnen mit Hirnmetastasen eines Mammakarzinoms im BMBC-Register (GBG-79)

Abstract P4-08-26: Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79)

Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial

Abstract PD5-05: Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial

Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study

Abstract P6-15-01: Withdrawn

Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)

Interstitial nephritis and high titers of PR3-ANCA: an unusual manifestation of ANCA-associated disease

Suchergebnisse filtern